IBIO Stock Summary and Trading Ideas (Ibio | NASDAQ:IBIO)

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Ibio trades on the NASDAQ stock market under the symbol IBIO.

As of December 24, 2025, IBIO stock price declined to $1.87 with 840,718 million shares trading.

IBIO has a beta of 0.19, meaning it tends to be less sensitive to market movements. IBIO has a correlation of 0.00 to the broad based SPY ETF.

IBIO has a market cap of $42.05 million. This is considered a Sub-Micro Cap stock.

Last quarter Ibio reported $100,000 in Revenue and -$.11 earnings per share. This beat revenue expectation by $45,000 and missed earnings estimates by -$.04.

In the last 3 years, IBIO traded as high as $52.00 and as low as $.56.

The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF.

IBIO has underperformed the market in the last year with a price return of -20.8% while the SPY ETF gained +17.3%. However, in the short term, IBIO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +134.5% vs +4.4% return in SPY. But in the last 2 weeks, IBIO shares have been beat by the market, returning -15.8% compared to an SPY return of +1.4%.

IBIO support price is $1.65 and resistance is $2.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.